Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Audrey Rabeau
Observed name:
A. Rabeau
Institutions:
Université Toulouse III - Paul Sabatier,
Centre Hospitalier Universitaire de Toulouse
Observed institutions:
Université Toulouse III - Paul Sabatier,
Centre Hospitalier Universitaire de Toulouse,
Institut universitaire du cancer de Toulouse Oncopole,
Hôpital Rangueil,
Hôpital Larrey,
Institut Claudius Regaud,
Université de Toulouse
show all 7
ORCID:
0000-0003-4175-3394
Observed ORCID:
0000-0003-4175-3394
OpenAlex ID:
A5036018448
Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
2019
·
Lizza E.L. Hendriks
, Clemence Henon
, et al.
·
Journal of Thoracic Oncology
·
253
PDF
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
2019
·
Jean-Louis Pujol
, Laurent Greillier
, et al.
·
Journal of Thoracic Oncology
·
194
PDF
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
2020
·
Guillaume Herbreteau
, Alexandra Langlais
, et al.
·
Journal of Clinical Medicine
·
53
PDF
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
2020
·
Fabrice Barlesi
, Adrien Dixmier
, et al.
·
OncoImmunology
·
42
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
2023
·
François-Xavier Danlos
, Matthieu Texier
, et al.
·
Cancer Discovery
·
33
PDF
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
2023
·
E. Pons-Tostivint
, P. Hulo
, et al.
·
Cancer Immunology Immunotherapy
·
27
PDF
Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer
2023
·
Corentin Pasquier
, Léonor Chaltiel
, et al.
·
Frontiers in Oncology
·
25
Granulomatose sarcoïdosique survenant sous inhibiteurs de point de contrôle immunitaire
2018
·
G. Faviez
, E. Bousquet
, et al.
·
Revue des Maladies Respiratoires
·
22
Diffuse alveolar haemorrhage secondary to e-cigarette “vaping” associated lung injury (EVALI) in a young European consumer
2020
·
Thomas Villeneuve
, Grégoire Prevot
, et al.
·
European Respiratory Journal
·
18
PDF
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial
2020
·
Bastien Cabarrou
, Carlos Gomez-Roca
, et al.
·
Investigational New Drugs
·
10
Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor
2024
·
Anne-Claire Toublanc
, Maxime Faure
, et al.
·
European Journal of Cancer
·
8
Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit
2018
·
Florent Puisset
, Laurence Bigay-Game
, et al.
·
Supportive Care in Cancer
·
8
LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways
2024
·
P. Tomasini
, C. Cropet
, et al.
·
Annals of Oncology
·
6
Binary Enterotoxin Producing Clostridium perfringens Isolated in Blood Cultures: Case Report and Review of the Literature
2024
·
Linda Ben Saïd
, Laure Diancourt
, et al.
·
Microorganisms
·
6
PDF
Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management
2020
·
Emmanuelle Vigarios
, Audrey Rabeau
, et al.
·
Lung Cancer
·
5
Bronchoscopic Multimodal Management of Tracheal Neurofibroma
2015
·
Audrey Rabeau
, Julien Mazieres
, et al.
·
Journal of Bronchology & Interventional Pulmonology
·
5
Pediatrician intervention impacts parental smoking in cystic fibrosis, diabetes, and bronchiolitis
2021
·
Maxime Lafont
, Carole Morin
, et al.
·
Pediatric Pulmonology
·
4
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
2023
·
E. Pons-Tostivint
, P. Hulo
, et al.
·
Cancer Immunology Immunotherapy
·
3
PDF
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
2025
·
Valérie Gounant
, Laurent Greillier
, et al.
·
JTO Clinical and Research Reports
·
2
PDF
Questions pratiques en immunothérapie dans le cancer bronchique non à petites cellules : dose, durée, rythme de traitement, réintroduction
2021
·
A. Rabeau
, J. Lavesque
, et al.
·
Revue des Maladies Respiratoires Actualités
·
2
Intérêt du crizotinib chez un patient porteur d’un cancer bronchique avec amplification de novo de MET
2016
·
A. Rabeau
, I. Rouquette
, et al.
·
Revue des Maladies Respiratoires
·
2
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial
2024
·
Mathilde Morisseau
, Carlos Gomez-Roca
, et al.
·
Investigational New Drugs
·
1
1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
2024
·
V. Gounant
, L. Greillier
, et al.
·
Annals of Oncology
·
1
PDF
378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma
2021
·
Francois-Xavier Danlos
, Capucine Baldini
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma
2021
·
F-X. Danlos
, C. Baldini
, et al.
·
Annals of Oncology
·
1
Show more works
View as search
Works count:
79
Citation count:
733
H-index:
10
I10-index:
10
Year
Topic
Type